MALMÖ, Sweden & WILMINGTON, DE — Clinical trial recruitment specialist Trialbee has secured a majority investment from Varsity Healthcare Partners, a deal that positions the company to rapidly scale its technology and global delivery as biopharma companies struggle with increasingly complex trial enrollment challenges.
The investment signals growing confidence in Trialbee’s data-driven approach to patient recruitment and its expanding role across global drug development programs. Financial terms were not disclosed, but the transaction gives Varsity Healthcare Partners a controlling stake, while existing backers MTIP and Industrifonden will remain minority investors.
Trialbee said the capital infusion will accelerate expansion of its Honey Platform, broaden enterprise-level recruitment offerings, and strengthen international delivery capabilities across its omnichannel partner ecosystem. The company operates at the intersection of patient identification, feasibility analysis, and site engagement, an area under mounting pressure as sponsors face delays that can add years and significant cost to drug development.
Chief Executive Officer Matt Walz said the partnership will allow the company to move faster and deliver greater predictability for sponsors, contract research organizations, and trial sites worldwide. He said the goal is to connect patients and research sites more precisely, helping studies enroll on time and within budget.
Over the past year, Trialbee has expanded its global footprint, working with more than 6,000 research sites across 50 countries and supporting trials in 66 languages. The company reported screening more than 1.5 million patients in 2025, aided by new sponsor-specific registries and deeper data partnerships designed to improve patient-aligned feasibility and enrollment projections.
Varsity Healthcare Partners, which focuses on healthcare services and technology businesses that support clinical operations at scale, said Trialbee fits its strategy of backing established platforms with room for operational expansion. Partner Navid Gharavi said the firm was drawn to Trialbee’s emphasis on customer outcomes and its ability to apply data and analytics to one of clinical research’s most persistent problems.
The deal arrives as biopharma sponsors face heightened scrutiny over trial timelines and enrollment performance, particularly as protocols grow more specialized and eligibility criteria tighten. Recruitment failures remain a leading cause of trial delays and cost overruns across the industry.
Trialbee said its leadership team and mission will remain unchanged as it enters its next phase of growth. Financial advisory firm Stout advised Trialbee on the transaction.
With fresh capital and a new majority owner, Trialbee is positioning itself as a scaled infrastructure partner for sponsors seeking to modernize how patients are identified, engaged, and enrolled in clinical trials worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.